RBC Capital raised the firm’s price target on NewAmsterdam Pharma to $31 from $25 and keeps an Outperform rating on the shares after its Q4 update. The company’s BROOKLYN and BROADWAY readouts remain on track for Q3 and Q4 of this year, and its PREVAIL study is looking to complete enrollment this quarter for a readout in 2026, the analyst tells investors in a research note. RBC adds that it remains confident in the likelihood of success for the phase 3 lipid lowering studies, and that the 40%-50% reductions in low-density lipoprotein can translate to highly meaningful cardiovascular benefits, unlocking a $1.3B U.S. opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NAMS:
- NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
- NewAmsterdam Pharma reports Q4 EPS ($2.15), consensus ($2.11)
- NewAmsterdam Pharma Launches Public Offering for Growth
- NewAmsterdam Pharma 4.49M share Spot Secondary priced at $19.00
- NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants